Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.34 |
| ▸ | CTSS | P25774 | 9/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052010 | 0.84 | CTSK (0.32) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL13461325 | 0.82 | GAA (0.41) | CTSKCTSSMEN1KMT2A | |
| SCHEMBL11469145 | 0.80 | CTSK (0.30) | CTSKCTSS | |
| SCHEMBL112861 | 0.80 | MCL1 (0.36) | CTSKCTSS | |
| SCHEMBL3290966 | 0.80 | CTSK (0.30) | CTSKCTSS | |
| SCHEMBL4706616 | 0.80 | CTSK (0.33) | CTSKCTSS | |
| SCHEMBL13818684 | 0.78 | CTSS (0.36) | CTSKCTSSCTSLCTSB | |
| SCHEMBL14775553 | 0.77 | — | — | |
| SCHEMBL19765225 | 0.77 | CTSS (0.35) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL10012454 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309706-B2 | Nucleosides; sodium/lithium/potassium peroxides as nucleophilic agents; solid phase synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20080076913-A1 | Methods of synthesizing oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | DELLINGER DOUGLAS J | 2008-03-27 | — | — | US | disclosed |
| US-7271258-B2 | Methods of synthesizing oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | AGILENT TECHNOLOGIES, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060252924-A1 | Methods of synthesizing oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2006-11-09 | — | — | US | disclosed |
| US-7101986-B2 | Methods of synthesizing oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | AGILENT TECHNOLOGIES, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1553102-A1 | Synthesis of oligonucleotides | Agilent Technologies, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-0984021-B1 | Synthesis of oligonucleotides | AGILENT TECHNOLOGIES INC (US) | 2005-04-27 | — | — | EP | disclosed |
| US-20040230052-A1 | Methods of synthesizing oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2004-11-18 | — | — | US | disclosed |
| US-6630581-B2 | Condensing the 3'-OH or 5'-OH group of a support-bound nucleoside or oligonucleotide with a monomeric nucleoside phosphoramidite having a carbonate-protected hydroxyl group; treating the intermediate provided with a deprotecting reagent | AGILENT TECHNOLOGIES, INC. | 2003-10-07 | — | — | US | disclosed |
| US-20020045221-A1 | Solid phase synthesis of oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2002-04-18 | — | — | US | disclosed |
| US-6222030-B1 | CONDENSING HYDROXY GROUP OF BOUND OLIGONUCLEOTIDE OR NUCLEOSIDE WITH NUCLEOSIDE PHOSPHORAMIDITE HAVING CARBONATE-PROTECTED HYDROXYL GROUP, TREATING WITH DEPROTECTING AGENT ALSO OXIDIZES PHOSPHITE TRIESTER LINKAGE | AGILENT TECHNOLOGIES, INC. | 2001-04-24 | — | — | US | disclosed |
| EP-0984021-A2 | Synthesis of oligonucleotides | Hewlett-Packard Company (US) | 2000-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252924-A1 | Methods of synthesizing oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | POLL, DNTT, RNGTT | CTSK 1669/4885CTSS 1998/4885CTSL 2754/4885 |
| US-20020045221-A1 | Solid phase synthesis of oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | POLL, RNGTT, DNTT | CTSK 2001/4885CTSS 2177/4885CTSL 2715/4885 |
| US-20040230052-A1 | Methods of synthesizing oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | POLL, DNTT, RNGTT | CTSK 1932/4885CTSS 2046/4885CTSL 3042/4885 |
| US-20080076913-A1 | Methods of synthesizing oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | POLL, DNTT, RNGTT | CTSK 1669/4885CTSS 1998/4885CTSL 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.